Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age Inzaule, S. C. Jordan, M. R. /Cournil, Amandine Vitoria, M. Ravasi, G. Cham, F. Le, L. V. Dzangare, J. Hamunime, N. Mutenda, N. /Aghokeng Fobang, Avelin Bissek, A. Billong, S. Kaleebu, P. Doherty, M. Bertagnolio, S. Use of dolutegravir-based first-line antiretroviral therapy (ART) in response to rising levels of pretreatment HIV drug resistance (PDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) may be limited, given safety concerns for birth defects in women of child-bearing potential. Pooled data from 11 nationally representative surveys show that NNRTI PDR in women is nearly twice that in men, exceeding 10% in 8 of 11 countries monitored, suggesting the urgent need for a non-NNRTI-based ART regimen in this population. 2019 text https://www.documentation.ird.fr/hor/fdi:010077424 fdi:010077424 Inzaule S. C., Jordan M. R., Cournil Amandine, Vitoria M., Ravasi G., Cham F., Le L. V., Dzangare J., Hamunime N., Mutenda N., Aghokeng Fobang Avelin, Bissek A., Billong S., Kaleebu P., Doherty M., Bertagnolio S.. Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age. 2019, 33 (11), 1797-1799 EN AFRIQUE SUBSAHARIENNE AMERIQUE LATINE ASIE DU SUD EST